Loading
A phase 2 trial of MRG003, Capecitabine, Docetaxel in nasopharyngeal carcinoma, run by Lepu Biopharma Co., Ltd., active and no longer recruiting.
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma is a phase 2 interventional study registered as NCT05126719 by Lepu Biopharma Co., Ltd., with 238 participants planned, started 2023-04-06 and due to reach its primary completion in 2024-12-30. Interventions recorded: MRG003, Capecitabine tablets, Docetaxel injection. Conditions listed: Recurrent or Metastatic Nasopharyngeal Carcinoma. No results are recorded here; the registry entry is the source.
Shares MRG003, Lepu Biopharma, Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma.
Shares MRG003, Lepu Biopharma.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma, Docetaxel, Capecitabine.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma.